Current FDA Status
- Phase 3 trials complete: Novo Nordisk completed Phase 3 REDEFINE 1 (obesity without diabetes) and REDEFINE 2 (obesity with type 2 diabetes) trials for CagriSema—a fixed-dose combination of cagrilintide 2.4mg + semaglutide 2.4mg
- REDEFINE 1 results: 22.7% mean weight loss at 68 weeks (published in NEJM, June 2025)
- REDEFINE 2 results: 15.7% weight loss at 68 weeks in patients with type 2 diabetes
- NDA (New Drug Application) filing: Expected Q1 2026
- FDA decision timeline: Projected late 2026 to early 2027 (assuming successful filing and standard review)
Safety and proof-of-concept
REDEFINE program trials
Application filing to FDA
6–12 month review period
FDA approval expected
Phase 3 Trial Results
CagriSema demonstrated exceptional weight loss across multiple Phase 3 trials:
- REDEFINE 1 (obesity without diabetes, NCT05567796): 22.7% mean weight loss at 68 weeks versus 2.3% with placebo. CagriSema outperformed both components alone: semaglutide 2.4mg (16.1%) and cagrilintide 2.4mg (11.8%).[1]
- REDEFINE 2 (obesity with type 2 diabetes): 15.7% weight loss at 68 weeks versus 3.1% with placebo—demonstrating efficacy even in more challenging metabolic populations.[2]
- Exceptional responder rates: In REDEFINE 1, 40.4% of participants achieved ≥25% weight loss, and 50.7% reached a non-obese BMI.[1]
- Cardiometabolic benefits: Systolic blood pressure reduction of -10.9 mmHg, and 87.7% of participants with prediabetes normalized glucose levels.[1]
- Safety profile: Most common side effect was nausea (55%), with 6.0% discontinuation rate due to adverse events—consistent with GLP-1 receptor agonist class safety.[1]
Dual-Mechanism Synergy
CagriSema combines cagrilintide (amylin analog) with semaglutide (GLP-1 agonist), targeting appetite regulation through two distinct pathways. The combination achieved 22.7% weight loss—significantly exceeding semaglutide alone (16.1%), demonstrating true pharmacological synergy rather than simple addition.
Development Timeline
CagriSema's development reflects Novo Nordisk's strategy to build on semaglutide's success by adding complementary amylin pathway activation. Here's how the program has progressed:
| Phase | Status | Timeframe | Description |
|---|---|---|---|
| Phase 1 (Safety & Dosing) | ✓ Complete | ~2020–2021 | First-in-human studies, combination safety assessment |
| Phase 2 (Proof-of-Concept) | ✓ Complete | 2021–2022 | 15.6% weight loss at 32 weeks (NCT04982575) |
| Phase 3 - REDEFINE 1 | ✓ Complete | 2023–2024 | 3,417 participants, obesity without T2D |
| Phase 3 - REDEFINE 2 | ✓ Complete | 2023–2025 | Obesity with type 2 diabetes |
| Phase 3 - REDEFINE 4 | ⟳ Ongoing | 2024–2026 | Head-to-head vs tirzepatide (800 participants) |
| Phase 3 - REDEFINE 11 | ⟳ Ongoing | 2025–2027 | Extended duration trial for additional efficacy/safety data |
| NDA Submission (Obesity) | ⧗ Pending | Q1 2026 | Formal filing for regulatory approval |
| FDA Review & Decision | ⊕ Projected | Late 2026/2027 | Approval decision expected |
Summary for Readers: CagriSema has successfully completed pivotal Phase 3 trials for obesity with and without diabetes. Novo Nordisk is conducting additional trials (REDEFINE 4 vs. tirzepatide, REDEFINE 11 for extended efficacy) to strengthen the regulatory package and competitive positioning.
Approval Milestones
| Milestone | Date | Status | Details |
|---|---|---|---|
| Phase 1 Completion | ~2021 | ✓ Complete | Safety, tolerability, PK/PD established |
| Phase 2 Enrollment | Aug-Oct 2021 | ✓ Complete | 92 participants across 17 US sites |
| Phase 2 Results | August 2022 | ✓ Complete | 15.6% weight loss at 32 weeks announced |
| Phase 3 Initiation | 2023 | ✓ Complete | REDEFINE 1 and REDEFINE 2 trials launched |
| REDEFINE 1 Results | December 20, 2024 | ✓ Complete | 22.7% weight loss announced |
| REDEFINE 2 Results | March 10, 2025 | ✓ Complete | 15.7% weight loss (T2D population) |
| NEJM Publication | June 22, 2025 | ✓ Complete | REDEFINE 1 peer-reviewed publication |
| REDEFINE 11 Initiation | June 2025 | ✓ Complete | Extended duration trial started |
| NDA Submission | Q1 2026 | ⧗ Pending | Application filing to FDA |
| FDA Acceptance for Review | ≈ 60 days post-submission | ◯ Future | Agency confirms completeness |
| PDUFA Date Set | Upon acceptance | ◯ Future | Target decision deadline assigned |
| REDEFINE 4 Results | 2026 | ⊕ Projected | Head-to-head vs tirzepatide data |
| FDA Decision (Obesity) | Late 2026/Early 2027 | ⊕ Projected | Assuming standard review timeline |
| Commercial Launch | 2027 | ⊕ Projected | If approved |
Summary for Readers: Novo Nordisk has systematically progressed CagriSema from early development through pivotal Phase 3 trials with consistently positive results. The Q1 2026 NDA filing target positions CagriSema for potential approval in late 2026 or early 2027.
Approval Predictions
Best-Case Scenario
Timeline: Late 2026 approval
What would need to happen:
- NDA submission early Q1 2026 (January-February)
- Priority Review granted (22.7% weight loss addresses unmet need)
- Clean safety profile with no manufacturing issues
- 6-month priority review instead of standard 10-12 months
- Approval by Q4 2026
Most Likely Scenario
Timeline: Early-to-mid 2027 approval
Assumptions:
- NDA submission Q1 2026 (March timeframe)
- Standard review (~10-12 months)
- Possible FDA questions about combination therapy long-term safety
- Advisory committee meeting to review dual-mechanism approach
- Approval Q1-Q2 2027
Delayed Scenario
Timeline: Late 2027 or later
Potential causes:
- NDA submission delayed beyond Q1 2026 to include REDEFINE 4 or 11 data
- FDA requests additional long-term cardiovascular outcomes data
- Complete Response Letter (CRL) requiring trial amendments
- Manufacturing/quality issues delaying submission or approval
Historical Comparison: Similar Drug Approvals
| Drug | Developer | Indication | NDA to Approval | Notes |
|---|---|---|---|---|
| Semaglutide (Wegovy) | Novo Nordisk | Obesity | ~7 months (priority) | Priority review granted; approved 2021 |
| Tirzepatide (Zepbound) | Eli Lilly | Obesity | ~6 months (priority) | Priority review granted; approved 2023 |
| Contrave (Naltrexone/Bupropion) | Orexigen/Takeda | Obesity (combination) | ~10 months (standard) | Combination therapy; approved 2014 |
Historical context: Recent obesity medications from Novo Nordisk have received priority review (6-8 month timeline). CagriSema's 22.7% weight loss and dual-mechanism approach position it as a strong candidate for priority designation, though combination therapies sometimes face additional scrutiny.
Summary for Readers: Based on Novo Nordisk's track record and CagriSema's compelling efficacy data, approval in late 2026 to early 2027 is most realistic. Priority review is likely but not guaranteed, which could shift the timeline by several months.
FDA Approval Process
Once Novo Nordisk submits its New Drug Application (NDA) for CagriSema, the drug will move through a structured FDA review process. Here's what that journey looks like:
NDA Submission
Novo Nordisk will submit a complete application package containing all Phase 3 clinical trial data from the REDEFINE program, manufacturing details, proposed labeling, and risk evaluation/mitigation strategies.
FDA Filing Decision
FDA reviews the application for completeness. If accepted, they assign a PDUFA date (the target decision deadline) and determine if it qualifies for Priority Review (6 months) or Standard Review (10-12 months).
FDA Review Period
FDA scientists evaluate safety, efficacy, manufacturing quality, and labeling. They may request additional data or schedule an advisory committee meeting if needed. For CagriSema, the FDA will carefully review the combination therapy's safety profile and the synergistic effects of cagrilintide + semaglutide.
PDUFA Date Decision
By the PDUFA date, the FDA must issue one of three decisions:
- Approval: Drug can be marketed
- Complete Response Letter: Issues need to be addressed before approval
- Extend review: More time needed (rare)
Summary for Readers: The FDA approval process typically takes 6-12 months after submission. CagriSema's compelling Phase 3 results and Novo Nordisk's strong regulatory track record support a relatively smooth review, though combination therapies may face additional questions about long-term safety.
Post-Approval Rollout
If Approved:
- 1-3 months - Commercial launch begins: Product stocked in pharmacies/specialty distributors
- 3-6 months - Payer negotiations: Formulary inclusion decisions; Novo Nordisk will emphasize 22.7% weight loss superiority over semaglutide alone
- 6-12 months - Broader insurance coverage: Patient-assistance programs and co-pay cards introduced
- Post-marketing studies: FDA may require Phase 4 studies to monitor long-term cardiovascular outcomes and combination therapy safety
If Delayed or Not Approved:
- The FDA could issue a Complete Response Letter (CRL) requesting more data on long-term safety, cardiovascular outcomes, or manufacturing quality
- Additional combination therapy safety data might be required, particularly for amylin pathway long-term effects
- Manufacturing or quality issues could delay approval by 6-18 months while Novo Nordisk addresses FDA concerns
- The company may wait to include REDEFINE 4 (vs. tirzepatide) or REDEFINE 11 data to strengthen competitive positioning
Summary for Readers: After FDA approval, most drugs reach pharmacies within 1-3 months. Insurance coverage typically follows within 6-12 months as payers complete formulary reviews and negotiate pricing. Novo Nordisk's established commercial infrastructure for Wegovy should enable a rapid CagriSema launch.
FAQs
Novo Nordisk expects to submit the NDA for CagriSema in Q1 2026. With a standard FDA review (10-12 months), approval would most likely occur in early-to-mid 2027. However, if CagriSema receives priority review (which is possible given its 22.7% weight loss efficacy), approval could come as early as late 2026.
No. CagriSema is not yet FDA-approved and is not available for prescription use. Access is currently limited to participants in clinical trials. You can search for active REDEFINE trials at ClinicalTrials.gov by searching "CagriSema" or "cagrilintide semaglutide."
The PDUFA date (Prescription Drug User Fee Act date) is the FDA's target deadline for completing its review of the NDA. It's typically set approximately 60 days after the FDA accepts the NDA for filing. For CagriSema, we'll likely know the PDUFA date in Q2 2026 (assuming a Q1 2026 NDA submission). This date gives patients, clinicians, and investors a concrete timeline for when to expect a decision.
CagriSema combines two complementary mechanisms:
- Semaglutide (GLP-1 agonist): The same ingredient in Wegovy, reduces appetite and slows gastric emptying
- Cagrilintide (amylin analog): Enhances satiety signaling and suppresses glucagon through a separate pathway
This dual approach achieves 22.7% weight loss—significantly exceeding semaglutide alone (16.1%). Zepbound (tirzepatide) uses a different dual mechanism (GLP-1 + GIP agonism) and achieves similar efficacy (20-22.5%). Direct head-to-head comparison data from the REDEFINE 4 trial is pending.
Insurance coverage will depend on several factors: FDA-approved indications, payer formulary decisions, and prior authorization requirements. Based on current GLP-1 coverage patterns, we expect:
- Obesity: Variable coverage; some insurers exclude obesity medications entirely, while others cover them with strict criteria (e.g., BMI ≥30 or ≥27 with comorbidity)
- Competitive positioning: CagriSema's 22.7% weight loss may justify premium formulary placement, though payers may initially favor single-agent therapies like Wegovy or Zepbound
Novo Nordisk will likely negotiate with payers for favorable formulary placement, and patient assistance programs will be available for those without coverage. More information will be available closer to launch.
CagriSema combines cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) because they target appetite regulation through two distinct but synergistic pathways. Clinical trials demonstrate true synergy: CagriSema (22.7% weight loss) exceeds semaglutide alone (16.1%) and cagrilintide alone (11.8%). By activating both GLP-1 and amylin pathways, CagriSema achieves superior weight loss with manageable side effects—demonstrating that 1 + 1 = 3 in this case.
Common reasons for approval delays include:
- Combination therapy scrutiny: FDA may require additional safety data for the amylin + GLP-1 combination, particularly long-term cardiovascular outcomes
- Manufacturing issues: Problems identified during FDA facility inspections for combination product manufacturing
- Complete Response Letter (CRL): FDA's formal notification that the application is not ready for approval, requiring resubmission
- Advisory committee meeting: The FDA may convene an external expert panel to review combination therapy data, which can add 3-6 months to the timeline
- Strategic delay: Novo Nordisk may choose to wait for REDEFINE 4 (vs. tirzepatide) or REDEFINE 11 data to strengthen the submission
Novo Nordisk's strong regulatory track record and CagriSema's compelling Phase 3 data reduce the likelihood of major delays, but they remain possible.
Both are dual-mechanism obesity therapies with similar efficacy:
- CagriSema: GLP-1 agonist + amylin analog; 22.7% weight loss at 68 weeks
- Tirzepatide (Zepbound): GLP-1 agonist + GIP agonist; 20-22.5% weight loss at 72 weeks
Direct head-to-head comparison data from the REDEFINE 4 trial (CagriSema vs. tirzepatide 15mg in 800 participants) is expected in 2026. This trial will provide definitive comparative efficacy and safety data to inform treatment decisions.
Sources & References
- Novo Nordisk. "CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM." Press Release, June 23, 2025. https://www.prnewswire.com/news-releases/cagrisema-2-4-mg--2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1--published-in-nejm-302487770.html
- Novo Nordisk. "CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial." Press Release, March 10, 2025. https://www.globenewswire.com/news-release/2025/03/10/3039539/0/en/Novo-Nordisk-A-S-CagriSema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-the-REDEFINE-2-trial.html
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. Published June 22, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2502081
- Novo Nordisk. "CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial." Press Release, December 20, 2024. https://www.globenewswire.com/news-release/2024/12/20/3000444/0/en/Novo-Nordisk-A-S-CagriSema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-in-the-REDEFINE-1-trial.html
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet. 2023. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01163-7/abstract
- ClinicalTrials.gov. "A Research Study to Look at How Well CagriSema Works in People Living With Obesity or Overweight (REDEFINE 1)." NCT05567796. https://clinicaltrials.gov/study/NCT05567796
- Pharmaceutical Technology. "Novo Nordisk plans new study for CagriSema, targets 2026 submission." June 2025. https://www.pharmaceutical-technology.com/news/novo-nordisk-plans-new-study-for-cagrisema-targets-2026-submission/
- BioPharma Dive. "Novo outlines new late-stage study of obesity drug CagriSema." June 2025. https://www.biopharmadive.com/news/novo-cagrisema-obesity-new-phase-3-trial-redefine-11/739267/
- U.S. Food and Drug Administration. "Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review." https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.